XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Oct 17th, 2006 - 02:03:55

Ebola Channel
subscribe to Ebola newsletter

Latest Research : Infectious Diseases : Ebola

   DISCUSS   |   EMAIL   |   PRINT
How Ebola and Marburg viruses cause disease
Oct 17, 2006, 02:01, Reviewed by: Dr. Priya Saxena

"This brilliant study shows that many viruses, including HIV, use a similar mechanism to disarm their victims. The Columbia study has shown us new ways to fight against deadly viruses the world over."

 
Researchers in the Greene Infectious Disease Laboratory at Columbia University's Mailman School of Public Health, the Centers for Disease Control and Prevention, and the Caribbean Primate Research Center have discovered a key mechanism by which the Filoviruses, Ebola and Marburg, cause disease. The identification of an amino acid sequence in Filoviruses that results in the rapid depression of immunological response is described in the December 2006 issue of The FASEB Journal. Using this information, researchers can begin to develop new drugs to stop these devastating diseases.

Filoviruses, named for their threadlike appearance in electron microscopy (filo= thread in Latin), are associated with outbreaks of fatal hemorrhagic fever in sub-Saharan Africa. Viral hemorrhagic fevers are of specific concern because they are associated with high morbidity and mortality (up to 80% mortality rates) and the potential for rapid dissemination through human-to-human transmission. The term "viral hemorrhagic fever" characterizes a severe multisystem syndrome associated with fever, shock, and bleeding caused by infection with one of a number of viruses, including the Filoviruses Ebola and Marburg.

Both humans and apes are susceptible to viral hemorrhagic fevers, and it is speculated that filovirus infections account at least in part for the recent decline in the gorilla and chimpanzee population in central Africa. There is no cure or approved vaccine for either Marburg or Ebola virus. Immunosuppression occurs early after infection and allows the viruses to reproduce rapidly and cause disease.

"Currently, there is no way to treat most viral hemorrhagic fever outbreaks, and increased international travel, trafficking in wildlife, political instability, and terrorism have made emerging infectious diseases a global concern," stated W. Ian Lipkin, MD, director of the Greene Infectious Disease Laboratory at the Mailman School's Department of Epidemiology and professor of Epidemiology, Neurology, and Pathology at Columbia University. "The identification of this new mechanism for immunosuppression is anticipated to lead to new drugs for intervention in filoviral hemorrhagic fevers of humans and apes."

In the study, researchers describe a series of amino acids in Ebola and Marburg viruses that resemble proteins in retroviruses known to suppress the immune system. By targeting these amino acids, new drugs could disrupt the ability of these viruses to shut down immune systems and make them vulnerable to the body's natural defenses.

"This brilliant study shows that many viruses, including HIV, use a similar mechanism to disarm their victims," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. "The Columbia study has shown us new ways to fight against deadly viruses the world over."

The method for discovering this protein underscores the power of bioinformatics for addressing the challenges of emerging infectious diseases. The investigators are currently exploring whether insights derived from understanding the potency of these immunosuppressive peptides can be exploited to treat autoimmune diseases.
 

- The FASEB Journal
 

www.fasebj.org

 
Subscribe to Ebola Newsletter
E-mail Address:

 

About the Mailman School of Public Health

The only accredited school of public health in New York City, and among the first in the nation Columbia University's Mailman School of Public Health provides instruction and research opportunities to more than 950 graduate students in pursuit of masters and doctoral degrees. Its students and more than 270 multi-disciplinary faculty engage in research and service in the city, nation, and around the world, concentrating on biostatistics, environmental health sciences, epidemiology, health policy and management, population and family health, and sociomedical sciences.

About the Jerome L. and Dawn Greene Infectious Disease Laboratory

The Jerome L. and Dawn Greene Infectious Disease Laboratory is located at the Mailman School of Public Health. In addition to establishing methods for diagnosis, prevention, and treatment of acute outbreaks of infectious disease, Laboratory scientists investigate links between infection and a wide range of chronic diseases including autism, attention deficit hyperactivity disorder, obsessive compulsive disorders, depression, schizophrenia, diabetes mellitus, and cancer that have their origins in early or even prenatal life.

About The FASEB Journal

The FASEB Journal (www.fasebj.org) is published by the Federation of American Societies for Experimental Biology (FASEB) and is consistently ranked among the top three biology journals worldwide by the Institute for Scientific Information. FASEB comprises 21 nonprofit societies with more than 80,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to enhance the ability of biomedical and life scientists to improve through their research the health, well-being and productivity of all people. FASEB serves the interests of these scientists in those areas related to public policy, facilitates coalition activities among member societies and disseminates information on biological research through scientific conferences and publications.


Related Ebola News

How Ebola and Marburg viruses cause disease
Simplified vaccine against Ebola virus developed
Ebola Virus Vaccine May Protect Against Sudan and Zaire Species
Ebola DNA vaccine produces immune responses : Phase 1 trial
Charting the Path of the Deadly Ebola (ZEBOV) Virus
Scientists discover how Ebola virus infects cells


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us